Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Tetsuaki Hirase"'
Autor:
Athanasius Wrin Hudoyo, Tetsuaki Hirase, Andreas Tandelillin, Masahiko Honda, Manabu Shirai, Jidong Cheng, Hiroko Morisaki, Takayuki Morisaki
Publikováno v:
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 23-29 (2017)
A high intake of products containing fructose is known to mediate insulin resistance. In the liver, AMPD2, an isoform of AMPD, has important glucose metabolic homeostasis functions including maintenance of AMP-activated protein kinase (AMPK). We spec
Externí odkaz:
https://doaj.org/article/abb3aaa6d3c446a097be4db3bab23fc3
Publikováno v:
Biochemistry and Biophysics Reports, Vol 5, Iss C, Pp 290-295 (2016)
Background and aims: Pentraxin-3 (PTX3) reportedly has protective roles in atherosclerosis and myocardial infarction, and is a useful biomarker of vascular inflammation. However, the detailed functions of PTX3 in inflammation are yet to be elucidated
Externí odkaz:
https://doaj.org/article/d878bbfef63a465385c1682b29bba2c0
Autor:
Hiroyuki Tsutsui, Hiroyuki Sakamaki, Shin-ichi Momomura, Yasushi Sakata, Yutaro Kotobuki, Stephan Linden, Odette S. Reifsnider, Pal Rakonczai, Matthew Stargardter, Tatsunori Murata, Tetsuaki Hirase, Daisuke Nitta
Publikováno v:
Journal of Cardiology. 81:522-530
Autor:
Arihiro Kiyosue, Julia P. Dunn, Xuewei Cui, Ana Hickey, Tetsuaki Hirase, Takeshi Imaoka, Robert J. Heine
Publikováno v:
Diabetes, obesitymetabolism.
To assess the safety and efficacy of tirzepatide in people of East Asian descent based on age and BMI. .Data of participants enrolled in East Asian countries in the SURPASS-1, -3, -4, -5, J-mono, and J-combo Phase 3 clinical trials were included. Par
Autor:
Keigo Hanada, Tetsuaki Hirase, Hirotaka Watada, Tatsunori Murata, Daisuke Yabe, Tomoo Okamura, Fumiko Yamamoto, Hiroyuki Sakamaki
Publikováno v:
Diabetes Therapy
Introduction We evaluated the cost-effectiveness of linagliptin in Japan by estimating the lifetime outcome based on clinical event rates from the Asian subpopulation of the CARMELINA trial. In CARMELINA, linagliptin added to standard of care (SoC) v
Publikováno v:
Diabetes Therapy
Introduction International clinical trials have shown that linagliptin significantly improves glycemic control and can be used at a single dose regardless of renal function in patients with type 2 diabetes (T2D). However, to date, no studies have eva
Autor:
Tomoo Okamura, Atsutaka Yasui, Stefan Kaspers, Tatsuroh Kaneko, Tetsuaki Hirase, Maximilian von Eynatten, Ganghyuck Lee
Publikováno v:
Diabetes Therapy
Introduction Empagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, ameliorates hyperglycemia in patients with type 2 diabetes (T2D) by inducing sustained glucosuria. Empagliflozin treatment was previously associated with a transient inc
Autor:
Manabu Shirai, Andreas Tandelillin, Hiroko Morisaki, Takayuki Morisaki, Tetsuaki Hirase, Jidong Cheng, Masahiko Honda, Athanasius Wrin Hudoyo
Publikováno v:
Molecular Genetics and Metabolism Reports
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 23-29 (2017)
Molecular Genetics and Metabolism Reports, Vol 13, Iss C, Pp 23-29 (2017)
A high intake of products containing fructose is known to mediate insulin resistance. In the liver, AMPD2, an isoform of AMPD, has important glucose metabolic homeostasis functions including maintenance of AMP-activated protein kinase (AMPK). We spec
Autor:
Tandelilin, Andreas AK1,2, Tetsuaki Hirase1, Hudoyo, Athanasius W1,2, Jidong Cheng1,3, Keiko Toyama1,4, Hiroko Morisaki1,4, Takayuki Morisaki1,4 morisaki@ri.ncvc.go.jp
Publikováno v:
BMC Endocrine Disorders. Jul2015, Vol. 15 Issue 1, p1-8. 8p. 5 Graphs.
Autor:
Tsunehisa Shibahara, Tetsuaki Hirase, Stefan Kaspers, Hiroyuki Sakamaki, Anastasia Ustyugova, Kohei Kaku, Masakazu Haneda, Tomoo Okamura, Anuraag R. Kansal, Rina Chin, Atsutaka Yasui, Tatsunori Murata, Naoyuki Hayashi
Publikováno v:
Clinical Therapeutics. 41:2021-2040.e11
Purpose The goal of this study was to assess the cost-effectiveness of empagliflozin in Japan based on the Asian subpopulation in the EMPA-REG OUTCOME trial. Methods The trial has shown a reduction in the risk for cardiovascular (CV) and renal events